MOTS-c is administered subcutaneously, often on a 3 to 5 times per week schedule
During treatment, your provider may monitor: IGF-1 levels glucose and insulin response cholesterol markers liver function kidney function thyroid markers sex hormones blood pressure symptom changes sleep quality energy levels appetite recovery speed body composition skin quality workout performance side effects Monitoring allows your provider to adjust the dosage, change the treatment timeline, pause therapy if needed, or switch to a better-suited peptide based on how your body responds
Do not use if the seal is broken, the solution is not clear, or particulate matter is visible
In psoriatic arthritis vs rheumatoid arthritis, psoriatic arthritis is more likely to affect the nails, scalp, and entire digits
At 12 mg, the trajectory suggests sustained loss well beyond the point where tirzepatide users at 15 mg have already plateaued